Spruce Biosciences (SPRB) Other Non-Current Liabilities (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Other Non-Current Liabilities of $3.9 million for Q1 2026, up 1342.49% quarter-over-quarter from $273000.0 in Q3 2024.
Spruce Biosciences (SPRB) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Other Non-Current Liabilities for 7 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (changed N/A YoY), while the FY2023 annual figure was $236000.0, up 46.58% from the prior year.
- Other Non-Current Liabilities climbed to $3.9 million in Q1 2026 per SPRB's latest filing, from $273000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.9 million in Q1 2026 and bottomed at $95000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $506166.7 across 4 years, with a median of $211000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 1087.5% — and 2024, when it increased 24.09%.
- Spruce Biosciences' Other Non-Current Liabilities stood at $161000.0 in 2022, then surged by 46.58% to $236000.0 in 2023, then grew by 15.68% to $273000.0 in 2024, then soared by 1342.49% to $3.9 million in 2026.
- Business Quant data shows SPRB's Other Non-Current Liabilities at $3.9 million in Q1 2026, $273000.0 in Q3 2024, and $262000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.32 Mn |
| Mar 31, 2026 | 3.94 Mn |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 262,000.00 |
| Mar 31, 2024 | 250,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Sep 30, 2023 | 220,000.00 |
| Jun 30, 2023 | 202,000.00 |
| Mar 31, 2023 | 181,000.00 |
| Dec 31, 2022 | 161,000.00 |
| Sep 30, 2022 | 139,000.00 |
| Jun 30, 2022 | 117,000.00 |
| Mar 31, 2022 | 95,000.00 |
| Dec 31, 2021 | 73,000.00 |
| Sep 30, 2021 | 51,000.00 |
| Jun 30, 2021 | 29,000.00 |
| Mar 31, 2021 | 8,000.00 |
| Dec 31, 2020 | 118,000.00 |
| Sep 30, 2020 | 95,000.00 |
| Dec 31, 2019 | 20,000.00 |